Understanding antibiotic dosing in critically ill children
Official title: Antibiotic Dosing in Pediatric Intensive Care
Run by University Hospital, Ghent · NCT02456974 · Data updated 2026-11-12
This study is trying to find the best antibiotic doses for critically ill children in the hospital to make sure they get effective treatment with fewer side effects.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Day to 16 Years |
| Sex | All |
| Enrollment | 640 (estimated) |
| Sponsor | University Hospital, Ghent Academic / other |
| Locations | 1 site (Ghent) |
| Status | Recruiting |
| Started | May 2012 |
| Main results expected | September 1, 2027 |
| Study ends | September 1, 2027 |
| Registry record updated | September 17, 2026 |
| Trial ID | NCT02456974 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are pediatric patients aged between 1.8 kg and 15 years who are receiving specific antibiotic treatments in a pediatric intensive care setting.
✕Probably not a fit
Patients who do not have a catheter in place for blood sampling or have known hypersensitivity to the antibiotics being studied may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on the pharmacokinetics of various antibiotics in critically ill neonates, infants, and children admitted to the pediatric intensive care unit. It involves blood sampling from patients receiving antibiotics such as amoxicillin-clavulanate, piperacillin-tazobactam, vancomycin, teicoplanin, and meropenem as part of their routine clinical care. The goal is to gather data that can help optimize antibiotic dosing in this vulnerable population, ensuring effective treatment while minimizing potential side effects.
Why it matters
Potential benefit: If successful, this study could lead to improved antibiotic dosing strategies that enhance treatment outcomes for critically ill pediatric patients.
How similar studies have gone: Other studies have explored antibiotic pharmacokinetics in pediatric populations, indicating potential for success in optimizing treatment approaches.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients admitted to the pediatric intensive care unit * patient age/weight : 1,8 kg-15 years * patient receiving antibiotic treatment (piperacillin-tazobactam, amoxicillin-clavulanate, vancomycin, teicoplanin, meropenem, ciprofloxacin, amikacin) via intermittent infusion regimen or continuous infusion according to institutional treatment guidelines * intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred) Exclusion Criteria: * no catheter in place for blood sampling * absence of parental/patient consent * known hypersensitivity to beta-lactam antibiotics, glycopeptides, fluoroquinolones, aminoglycosides * extracorporeal circuit (haemodialysis, ECMO, peritoneal dialysis )
Where it's running
-
Ghent University Hospital, Hospital Pharmacy
Ghent, Belgium Recruiting
Study contacts
- Principal investigator: Pieter De Cock — University Hospital, Ghent
- Study coordinator: Pieter De Cock, PharmD
- Email: pieter.decock@uzgent.be
- Phone: +32 9 332 29 69
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating antibiotic dosing in critically ill children on ECMO
This study is testing if the current antibiotic doses are strong enough to help critically ill children on ECMO get better.
-
Precision dosing of beta-lactam antibiotics in critically ill children
This study tests whether using model-informed precision dosing can help critically ill kids reach target antibiotic levels earlier when treated with amoxicillin-clavulanate, piperacillin-tazobactam, or meropenem.
-
Levetiracetam Dosing in Critically Ill on CRRT
This study tests how levetiracetam behaves in the bodies of adults on continuous renal replacement therapy to help figure out the best dosing.
-
Trigonelline Monohydrate for NAD+ Metabolism in Healthy Adults
A small study in healthy adults tests whether taking trigonelline monohydrate by mouth for 4 weeks can change NAD+ levels and how the body handles the supplement, compared with NMN and placebo.
-
Cetuximab bioequivalence test in healthy men
This study tests whether a cetuximab injection is bioequivalent to Erbitux in healthy men to see if they behave the same in the body.
-
GenSci142 as a vaginal treatment for bacterial vaginosis
This study tests whether GenSci142 given as vaginal doses is safe and may help BV patients aged 18–50 compared with clindamycin cream.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.